KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
about
Oncogene Mutation Survey in MPNST Cell Lines Enhances the Dominant Role of Hyperactive Ras in NF1 Associated Pro-Survival and Malignancy.Diagnostic challenges of motility disorders: optimal detection of CD117+ interstitial cells of Cajal.Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival.
P2860
KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
KIT immunohistochemistry and m ...... d for treatment with imatinib.
@ast
KIT immunohistochemistry and m ...... d for treatment with imatinib.
@en
type
label
KIT immunohistochemistry and m ...... d for treatment with imatinib.
@ast
KIT immunohistochemistry and m ...... d for treatment with imatinib.
@en
prefLabel
KIT immunohistochemistry and m ...... d for treatment with imatinib.
@ast
KIT immunohistochemistry and m ...... d for treatment with imatinib.
@en
P2093
P2860
P1433
P1476
KIT immunohistochemistry and m ...... ed for treatment with imatinib
@en
P2093
Kovalenko S
Loughrey MB
Zalcberg J
P2860
P356
10.1111/J.1365-2559.2006.02464.X
P577
2006-07-01T00:00:00Z